APYX Q2 2025: Aon Demand Spurs $3M Guidance Hike as OEM Weakness Persists
APYX’s second quarter revealed a decisive pivot toward advanced energy platforms, with the Aon system’s early momentum prompting a $3 million annual revenue guidance increase despite ongoing OEM sales contraction. Strategic hires and a China expansion highlight a refocused growth playbook, while cost discipline and cash burn reduction underpin the company’s renewed flexibility heading into a pivotal commercial launch cycle.
Summary
- Aon Launch Reshapes Growth Narrative: Early demand for the next-gen body contouring system is outpacing expectations and driving a guidance raise.
- Cost Structure Reset: Restructuring and expense controls have sharply reduced losses and preserved cash, enabling investment in growth initiatives.
- Global Expansion Levers: New leadership and China market entry position APYX for multi-region advanced energy adoption.
Performance Analysis
APYX’s Q2 performance underscored a business in transition, with total revenue declining 6 percent year over year to $11.4 million, as anticipated OEM (original equipment manufacturing, third-party device production) sales softness offset stable advanced energy growth. Advanced energy, now the overwhelming majority of revenue, held steady at $9.7 million, reflecting the company’s strategic focus on proprietary platforms like Renuvion and the newly launched Aon system.
OEM segment sales fell 29 percent, a direct result of lower volumes with legacy partners such as Symmetry Surgical, highlighting the intentional deprioritization of lower-margin manufacturing contracts. Gross margin improved modestly, aided by cost reductions, as operating expenses dropped sharply to $9.7 million, down 25 percent from the prior year, mainly through headcount, SG&A (selling, general, and administrative, core operating costs), and R&D (research and development) cuts. The company’s adjusted EBITDA loss narrowed 54 percent, and cash burn was reduced to $1.2 million, reflecting improved financial discipline.
- Advanced Energy Anchors Revenue Base: Segment now comprises nearly 85 percent of total sales, underscoring the shift away from OEM dependency.
- Cost Structure Realignment: Operating expense reductions and cash burn control have materially extended the company’s runway.
- Seasonality May Shift: The timing of Aon shipments could disrupt typical Q3/Q4 revenue patterns, concentrating growth in the fourth quarter.
Overall, APYX’s improved cost profile and early Aon traction are offsetting OEM headwinds, setting the stage for a more focused, higher-margin growth trajectory in the back half of the year.
Executive Commentary
"The reaction from the doctors has been nothing short of spectacular so far since we've launched Aon...the interest in Aon goes beyond anything that we were anticipating just a few months ago, which is what pushed us to update our revenue targets for 2025."
Charlie Goodwin, President and Chief Executive Officer
"We are pleased to see the results of the cost-cutting measures taken in the fourth quarter of 2024 in our current numbers...we will yield cash through 2027."
Matt Hill, Chief Financial Officer
Strategic Positioning
1. Advanced Energy Focus and Aon Commercialization
APYX is accelerating its transition from OEM manufacturing to proprietary advanced energy solutions, with the Aon system representing a flagship all-in-one platform for body contouring. The company’s Ambassador program is seeding key opinion leaders with early units, refining go-to-market processes and building clinical advocacy ahead of a broader September launch. Management expects Aon’s comprehensive workflow integration, designed by and for surgeons, to drive adoption despite broader capital equipment spending caution in the aesthetics industry.
2. Renuvion and GLP-1 Tailwind
Renuvion, APYX’s minimally invasive skin-tightening device, is positioned to benefit from the surge in patients experiencing skin laxity post-weight loss, especially those using GLP-1 (glucagon-like peptide-1, weight loss medication) drugs. With over 15 million U.S. patients on GLP-1s, management sees a structural demand shift for body contouring procedures, supporting both Renuvion and Aon’s addressable market expansion.
3. International Expansion and China Entry
APYX’s entry into China via a distribution agreement with Glammoon Medical Technology opens a significant new market, leveraging Glammoon’s network of aesthetic facilities and targeting the country’s 5,000 plastic surgeons. Early marketing campaigns have generated strong initial response, and management expects China to become a sustained revenue contributor over the next several years.
4. Commercial Leadership Upgrades
Recent hires of John Featherstone (North America) and Simon Davies (Europe/Asia) bring deep aesthetics market experience, aiming to accelerate adoption of both Aon and Renuvion across key geographies. Leadership views these additions as critical to scaling commercial execution and capturing share in a competitive, innovation-hungry market.
Key Considerations
APYX’s Q2 marks a strategic inflection, with the company simultaneously executing a product-led growth strategy and maintaining operational discipline. The following considerations are critical for investors assessing the next phase:
Key Considerations:
- Aon Ramp as Growth Catalyst: Sustained demand beyond early adopters will be key to validating the platform’s market fit and revenue durability.
- OEM Drag Remains: Continued contraction in OEM sales could pressure top-line growth if advanced energy adoption underdelivers.
- China Execution Risk: Success in China hinges on Glammoon’s ability to scale Renuvion placements and navigate regulatory and competitive dynamics.
- Cost Discipline Must Persist: Maintaining lean operations is essential to support investment in commercial expansion without eroding margin gains.
Risks
APYX faces several material risks, including execution risk around the Aon commercial rollout, potential delays or lower-than-expected uptake in China, and continued weakness in OEM revenue that could dilute the impact of advanced energy growth. Tariff policy uncertainty and macroeconomic softness in capital equipment spending remain persistent headwinds. If Aon fails to scale rapidly, margin and cash flow improvements could stall.
Forward Outlook
For Q3 and Q4 2025, APYX guided to:
- Full-year revenue of $50 million to $52 million (raised from $47.6 million to $49 million previously)
- Advanced energy revenue of $42 million to $44 million (up from $39.6 million to $41 million)
For full-year 2025, management maintained:
- Gross margin of approximately 60 percent
- Total operating expenses not to exceed $40 million
Management highlighted several factors that will shape the second half:
- Aon shipment timing may shift typical seasonality, with Q4 likely to be strongest
- Cash burn expected to remain controlled, supporting investment in Aon and international launches
Takeaways
APYX’s Q2 signals the company’s most credible pivot yet to a proprietary, high-margin product model, with Aon’s launch and Renuvion’s GLP-1 tailwind positioned as core growth drivers.
- Advanced Energy Momentum: Aon’s early demand and Renuvion’s expanding addressable market are offsetting OEM contraction and driving a more focused revenue mix.
- Operational Leverage: Cost cuts and cash management have extended the runway, enabling APYX to invest in commercial and international expansion without sacrificing margin progress.
- Execution Watchpoint: The next two quarters are critical for proving Aon’s broader market appeal and for scaling China operations, both of which will determine if the guidance raise is sustainable.
Conclusion
APYX enters the back half of 2025 with a sharpened growth thesis anchored by Aon’s outperformance and disciplined cost management. Sustained momentum in advanced energy and successful international execution will be pivotal to realizing the company’s aspiration of becoming a leading surgical aesthetics partner.
Industry Read-Through
The strong Aon launch signals a potential inflection in surgeon appetite for innovation in a capital equipment market that has been subdued for several years. If APYX’s experience is indicative, pent-up demand for multifunctional, workflow-driven systems may be underestimated across the aesthetics sector. Renuvion’s GLP-1 tailwind highlights how adjacent health trends (such as weight loss drugs) can rapidly expand the addressable market for device makers. OEM contraction at APYX is a cautionary signal for legacy device manufacturers reliant on third-party contracts, and underscores the margin benefits of proprietary product strategies. China’s early traction suggests global demand for body contouring solutions remains robust, but execution and local partnerships are critical for sustained success.